Seres Therapeutics (1S90) Stock Statistics & Valuation Metrics

Seres Therapeutics has a market cap or net worth of €62.90M. The enterprise value is €124.83M.

Seres Therapeutics has 9,632,111 shares outstanding. The number of shares has decreased by -2.65% in one year.

Seres Therapeutics’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is -72.70%.

The current PE Ratio of Seres Therapeutics is ―. Seres Therapeutics’s PEG ratio is -0.22.

In the last 12 months, Seres Therapeutics had revenue of 789.00K and earned 5.70M in profits. Earnings per share was 0.64.

In the last 12 months, operating cash flow was -42.15M and capital expenditures -218.00K, giving a free cash flow of -42.37M billion.

Seres Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Seres Therapeutics upcoming earnings date is Aug 4, 2026, Before Open (Confirmed).

Seres Therapeutics as a current ratio of 2.56, with Debt / Equity ratio of 303.78%

In the past 12 months, Seres Therapeutics has paid 0.00 in taxes.

Seres Therapeutics EV to EBITDA ratio is -1.88, with an EV/FCF ratio of 195.40.

Seres Therapeutics has €29.83M in cash and marketable securities with €80.50M in debt, giving a net cash position of -€50.66M billion.

Gross margin is -20.92%, with operating margin of -11910.14%, and net profit margin of 721.93%.

The average price target for Seres Therapeutics is €17.81, which is 11.43% higher than the current price. The consensus rating is Moderate Buy